No Data
Wanbang Pharmaceutical: Report for the third quarter of 2024
Wanbang Pharmaceutical (301520.SZ) released its performance for the first three quarters, with a net income of 77.7975 million yuan, a year-on-year increase of 0.63%.
Wanbang Pharmaceutical (301520.SZ) released its third quarter report for 2024. In the first three quarters, the company achieved revenue...
万邦医药 (301520.SZ): The net income for the first three quarters was 77.7975 million yuan, a year-on-year increase of 0.63%.
Geneva News, October 24th - Wanbang Pharmaceutical (301520.SZ) released the third quarter report for 2024, with a revenue of 0.293 billion yuan in the first three quarters, a year-on-year increase of 21.88%; net income attributable to shareholders of listed companies was 77.7975 million yuan, a year-on-year increase of 0.63%; net income attributable to shareholders of listed companies after deducting non-recurring gains and losses was 55.8997 million yuan, a year-on-year decrease of 21.08%; basic earnings per share were 1.17 yuan.
Is Anhui Wanbang Pharmaceutical Technology Co.,Ltd.'s (SZSE:301520) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Wanbang Pharmaceutical (301520.SZ) approximately 5.4068 million restricted shares will be listed for public trading on September 25th.
Wanbang Pharmaceutical (301520.SZ) issued an announcement that the shares to be released from the restriction this time are the shares that have been issued before the company's initial public offering...
Anhui Wanbang Pharmaceutical Technology: Half-year report for the year 2024.
No Data
No Data